ALOXE3

Across TCGA pan-cancer cohorts, ALOXE3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ALOXE3 data layer compared with 29 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher ALOXE3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ALOXE3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, HNSC, and LUAD are the cancer types where ALOXE3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
HNSC	DFS	Median	III,IV	0.148	0.682	<.001	12	view →
LUAD	OS	Median	IV	0.153	0.714	.012	9	view →
UCEC	DFS	Median	All	0.961	0.618	.013	8	view →
SARC	DFS	Median	All	0.024	0.611	<.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ALOXE3–DLBC (DFS)

Open the DLBC breakdown →